谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients Without Oxygen Therapy: A Randomized, Phase III Clinical Trial.

Shinkai Masaharu,Tsushima Kenji, Tanaka Shingo,Hagiwara Eri,Tarumoto Norihito,Kawada Ichiro,Hirai Yuji,Fujiwara Sho,Komase Yuko,Saraya Takeshi,Koh Hidefumi,Kagiyama Naho,Shimada Megumi,Kanou Daiki,Antoku Shinichi,Uchida Yujiro,Tokue Yutaka,Takamori Mikio,Gon Yasuhiro,Ie Kenya,Yamazaki Yoshitaka,Harada Kazumasa,Miyao Naoki,Naka Takashi,Iwata Mitsunaga,Nakagawa Atsushi,Hiyama Kazutoshi,Ogawa Yoshihiko,Shinoda Masahiro,Ota Shinichiro,Hirouchi Takatomo,Terada Jiro,Kawano Shuichi,Ogura Takashi,Sakurai Tsutomu, Matsumoto Yoshihiko,Kunishima Hiroyuki,Kobayashi Osamu,Iwata Satoshi

Infectious diseases and therapy（2021）

引用 46|浏览15
暂无评分
关键词
COVID-19,Favipiravir,Oral antiviral agent,Phase III clinical trial,Moderate pneumonia not requiring oxygen therapy,SARS-CoV-2,Treatment efficacy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要